NASDAQ:ACIU
AC Immune SA Stock News
$3.18
-0.230 (-6.74%)
At Close: May 17, 2024
Detailed Data From the Phase II Crenezumab Alzheimer’s Prevention Initiative Study in Autosomal Dominant Alzheimer’s Disease Presented at AAIC
03:00pm, Tuesday, 02'nd Aug 2022 GlobeNewswire Inc.
LAUSANNE, Switzerland, Aug. 02, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (Nasdaq: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today a
AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates
12:45pm, Thursday, 28'th Jul 2022 Zacks Investment Research
AC Immune (ACIU) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates
10:11am, Thursday, 28'th Jul 2022
AC Immune (ACIU) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
AC Immune Announces Upcoming Presentations at the Alzheimer’s Association International Conference
11:30am, Friday, 22'nd Jul 2022 GlobeNewswire Inc.
LAUSANNE, Switzerland, July 22, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative disea
InflaRx Climbs More Than 40%, Here's 58 Biggest Movers From Yesterday
08:25am, Wednesday, 29'th Jun 2022 Benzinga
Gainers
Agile Therapeutics, Inc. (NASDAQ: AGRX) shares climbed 89.8% to close at $2.41 on Tuesday. Agile Therapeutics shares climbed over 10% on Monday amid the Supreme Court overturning Roe V Wade.
AC Immune Holds Annual General Meeting of Shareholders
08:30pm, Friday, 24'th Jun 2022 GlobeNewswire Inc.
LAUSANNE, Switzerland, June 24, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today a
Roche Alzheimer's Candidate Failure Hurts Lilly, Biogen
12:31pm, Friday, 17'th Jun 2022 Zacks Investment Research
Eli Lilly (LLY) and Biogen's (BIIB) Alzheimer's candidates, anti-amyloid beta antibodies, are in late-stage development and are expected to be launched in a few months.
In a tough, post-Fed market, strategist finds opportunity knocking in a couple of this year's hottest sectors
12:16pm, Thursday, 16'th Jun 2022 MarketWatch
A tough U.S. session is setting up, and one strategist has sifted through the market rubble to find opportunities.
AC Immune shares slide 15% premarket after trial of Alzheimer's treatment misses its main goals
06:39am, Thursday, 16'th Jun 2022
Shares of biotech AC Immune SA ACIU, -9.21% slid 15% in premarket trade Thursday, after the company said a a trial of a treatment for Alzheimer's disease failed to slow or prevent cognitive decline in
AC Immune Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease
05:00am, Thursday, 16'th Jun 2022 GlobeNewswire Inc.
Crenezumab did not statistically significantly slow or prevent cognitive decline in people with a specific genetic mutation which causes early-onset Alzheimer’s disease
AC Immune to Present at the 2022 Jefferies Healthcare Conference
11:30am, Tuesday, 31'st May 2022 GlobeNewswire Inc.
LAUSANNE, Switzerland, May 31, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today an
AC Immune to Present at the 2022 Jefferies Healthcare Conference
07:30am, Tuesday, 31'st May 2022
LAUSANNE, Switzerland, May 31, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today anno
AC Immune’s Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology
03:00pm, Monday, 09'th May 2022 GlobeNewswire Inc.
First study of an anti-Abeta vaccine in people living with Down syndrome (DS)
AC Immune Reports First Quarter 2022 Financial Results and Provides Corporate Update
11:30am, Thursday, 28'th Apr 2022 GlobeNewswire Inc.
Two clinical readouts delivered in Q1; five more expected by year-end
AC Immune to Present at the B. Riley Annual Neuro & Ophthalmology Virtual Investor Conference
11:55am, Wednesday, 27'th Apr 2022 GlobeNewswire Inc.
LAUSANNE, Switzerland, April 27, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today
